12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Company News  |  Other News

sanofi-aventis, National Institutes of Health metabolic news

Fabry's disease patients and their family members sent a petition to NIH asking the agency to re-examine a request from last year for the agency to exercise its march in powers under the federal Bayh-Dole Act to grant an open license to two U.S. patents covering the production of Fabry's disease drug Fabrazyme agalsidase...

Read the full 259 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >